Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)
RAPT Therapeutics Analyst Ratings
H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $10
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $6
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $6
Analysts Are Bullish on Top Healthcare Stocks: RAPT Therapeutics (RAPT), GE Healthcare Technologies Inc (GEHC)
Rapt Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
RAPT Therapeutics Analyst Ratings
HC Wainwright & Co. Upgrades RAPT Therapeutics to Buy, Maintains Price Target to $10
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Raises Target Price to $6
Wells Fargo Raises RAPT Therapeutics' Price Target to $6 From $4, Overweight Rating Maintained
H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Hold Rating
RAPT Therapeutics: Hold Rating Amid Strategic Uncertainties and Financial Resilience
Stifel Maintains RAPT Therapeutics(RAPT.US) With Hold Rating, Maintains Target Price $2
Piper Sandler Maintains RAPT Therapeutics(RAPT.US) With Hold Rating, Cuts Target Price to $2
Stifel Nicolaus Downgrades RAPT Therapeutics to Hold From Buy, Cuts Price Target to $2 From $7
A Quick Look at Today's Ratings for RAPT Therapeutics(RAPT.US), With a Forecast Between $2 to $4
A Quick Look at Today's Ratings for RAPT Therapeutics(RAPT.US), With a Forecast Between $4 to $4
RAPT Therapeutics Analyst Ratings
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $17